



Supplementary Figure 1 Overall survival of patients with stage IV gastric cancer who underwent jejunostomy and others-clinical stage IV gastric cancer patients ($P < 0.001$). GC: Gastric cancer.

Supplementary Table 1 Clinical characteristics of all patients with stage IV gastric cancer who underwent jejunostomy (*n* = 80)

Variables	Jejunostomy	
	<i>n</i> = 80	%
Sex		
Female	30	37.5
Male	50	62.5
Age (years)		
Mean (SD)	62.4 (12.8)	
< 65	46	57.5
≥ 65	34	42.5
Body mass index (kg/m²)		
Mean (SD)	21.0 (3.9)	
< 18.5	57	71.25
≥ 18.5	23	28.75
Charlson's comorbidity index (CCI)		
0	60	75.0
≥ 1	20	25.0
American Society of Anesthesiologists (ASA) class		
ASA I/II	41	51.25
ASA III/IV	39	48.75
Hemoglobin (g/dL)		
Mean (SD)	10.8 (2.2)	
≤ 11	40	50.0
> 11	40	50.0
Albumin (g/dL)		
Mean (SD)	3.4 (0.6)	
< 3.5	31	38.75
≥ 3.5	49	61.25
Neutrophil-lymphocyte ratio (NLR)		
Mean (SD)	6.28 (5.72)	

< 2.5	24	30.0
≥ 2.5	56	70.0
Presence of ascites on CT		
Absent	31	38.75
Present	49	61.25
Lauren type		
Intestinal	22	27.5
Diffuse/mixed	48	60.0
Undetermined	10	12.5
Tumor location		
Distal third	15	18.75
Middle third	54	67.5
Upper third	11	13.75
Gastric remnant tumor		
No	64	80.0
Yes	16	20.0
Tumor size (cm)		
Mean (SD)	7.3 (3.0)	
≤ 7 cm	38	47.5
> 7 cm	42	52.5
Peritoneal metastasis		
No	29	36.25
Yes	51	63.75
Distant metastasis		
No	66	82.5
Yes	14	17.5
Number of disease sites		
One (only locoregional)	24	30.0
Two or more	56	70.0
Postoperative complication (POC)		
None/Clavien 1-2	69	86.25

Clavien 3-5	11	13.75
Length of hospital stay (days)		
Mean (SD)	6.1 (4.9)	
Median (IQR)	4 (3-8)	
Palliative treatment		
1 st Line	41	51.25
2 nd Line	15	18.75
3 rd Line	2	2.5
Radiotherapy	7	8.75
Mortality		
30-d	25	31.25
90-d	41	51.25

SD: Standard deviation; CT: Computed tomography; IQR: Interquartile range.

Supplementary Table 2 Multivariate model for 90-d mortality risk factors (*n* = 40)

90-d mortality	Multivariate		
Variables	OR	95% CI	P value
Female (<i>vs</i> Male)	2.18	0.38-12.52	0.384
Age \geq 65 (<i>vs</i> < 65 years)	1.05	0.17-6.56	0.958
BMI < 18.5 (<i>vs</i> \geq 18.5)	0.43	0.03-5.73	0.520
ASA III/IV (<i>vs</i> I/II)	2.74	0.42-17.86	0.291
Charlson \geq 1 (<i>vs</i> 0)	2.12	0.25-17.96	0.489
Hb < 11 (<i>vs</i> \geq 11)	0.18	0.02-1.133	0.093
Alb < 3.5 (<i>vs</i> \geq 3.5)	0.96	0.13-7.10	0.967
NLR \geq 2.5 (<i>vs</i> < 2.5)	14.69	1.08-200.68	0.044
Ascites on CT (<i>vs</i> absent)	1.58	0.21-11.76	0.655
Tumor size > 7 cm (\leq 7 cm)	2.01	0.19-10.92	0.728
Two or more disease sites (<i>vs</i> one)	2.01	0.28-14.30	0.487

OR: Odds ratio; CI: Confidence interval; ASA: American Society of Anesthesiologists; BMI: Body mass index; Hb: Hemoglobin; Alb: Albumin; NLR: Neutrophil-lymphocyte ratio; CT: Computed tomography.